- Home
- BETR vs CERS Comparison
BETR vs CERS Comparison
Compare BETR & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BETR
- CERS
- Stock Information
- Founded
- BETR 2014
- CERS 1991
- Country
- BETR United States
- CERS United States
- Employees
- BETR N/A
- CERS N/A
- Industry
- BETR Finance: Consumer Services
- CERS EDP Services
- Sector
- BETR Finance
- CERS Technology
- Exchange
- BETR Nasdaq
- CERS Nasdaq
- Market Cap
- BETR 203.4M
- CERS 237.7M
- IPO Year
- BETR N/A
- CERS 1997
- Fundamental
- Price
- BETR $17.93
- CERS $1.27
- Analyst Decision
- BETR
- CERS Strong Buy
- Analyst Count
- BETR 0
- CERS 2
- Target Price
- BETR N/A
- CERS $3.50
- AVG Volume (30 Days)
- BETR 51.8K
- CERS 1.2M
- Earning Date
- BETR 08-13-2025
- CERS 08-05-2025
- Dividend Yield
- BETR N/A
- CERS N/A
- EPS Growth
- BETR N/A
- CERS N/A
- EPS
- BETR N/A
- CERS N/A
- Revenue
- BETR $130,672,000.00
- CERS $192,510,000.00
- Revenue This Year
- BETR $55.38
- CERS $24.95
- Revenue Next Year
- BETR $71.18
- CERS $11.88
- P/E Ratio
- BETR N/A
- CERS N/A
- Revenue Growth
- BETR 69.42
- CERS 13.25
- 52 Week Low
- BETR $7.71
- CERS $1.12
- 52 Week High
- BETR $21.80
- CERS $2.39
- Technical
- Relative Strength Index (RSI)
- BETR 65.01
- CERS 47.80
- Support Level
- BETR $12.74
- CERS $1.23
- Resistance Level
- BETR $18.47
- CERS $1.38
- Average True Range (ATR)
- BETR 1.44
- CERS 0.07
- MACD
- BETR 0.29
- CERS -0.00
- Stochastic Oscillator
- BETR 90.58
- CERS 50.00
About BETR Better Home & Finance Holding Company
Better Home & Finance Holding Co is a digital-first homeownership company whose services include mortgage, real estate, title, and homeowners insurance. The company has combined technology innovation and fresh thinking with a deep customer focus with the goal of revolutionizing the homeownership industry.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.